Update cardiologico

/Update cardiologico
- 09/2016


settembre 2016|Linee guida, News, Update cardiologico|0 Comments

Pubblicate il 27 Agosto 2016 le nuove linee-guida ESC sulla gestione delle dislipidemie. Le principali novità riguardano la messa a punto di un regime alimentare specifico in base all'obiettivo che ci si pone, che può essere quello di ridurre il colesterolo complessivo oppure di aumentare l'HDL. Rivisitati, infatti, gli alimenti da preferire e da evitare,

- 07/2016

Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals

luglio 2016|News, Update cardiologico|0 Comments

Importance  Heart disease (HD) and cancer are the 2 leading causes of death in the United States. During the first decade of the 21st century, HD mortality declined at a much greater rate than cancer mortality and it appeared that cancer would overtake HD as the leading cause of death. Objectives  To determine whether changes

- 07/2016

Prognostic Implications of LV Strain Risk Score in Asymptomatic Patients With Hypertensive Heart Disease ONLINE FIRST

luglio 2016|Cardiologia: presente e futuro... Discutiamone, News, Update cardiologico|0 Comments

Abstract Objectives  This study sought to investigate the associations of left ventricular (LV) strain and its serial change with major adverse cardiac events (MACE) in hypertensive heart disease, independent of and incremental to clinical and LV geometric parameters. Background  In patients with hypertensive heart disease, MACE are associated with abnormal LV morphology, but their association

- 07/2016


luglio 2016|Update cardiologico|0 Comments

lettera congiunta Società Scientifiche a Ministro Lorenzin 2-signed

- 06/2016

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study

giugno 2016|News, Update cardiologico|0 Comments

Objective To study the effectiveness and safety of the non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) dabigatran, rivaroxaban, and apixaban compared with warfarin in anticoagulant naïve patients with atrial fibrillation. Design Observational nationwide cohort study. Setting Three Danish nationwide databases, August 2011 to October 2015. Participants 61  678 patients with non-valvular atrial fibrillation who were naïve to

- 06/2016

Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary

giugno 2016|News, Update cardiologico|0 Comments

In 2013, the European Heart Rhythm Association (EHRA) published a Practical Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) (Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A. European Heart Rhythm Association Practical Guide on

- 06/2016

Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54

giugno 2016|News, Update cardiologico|0 Comments

Background  Patients with diabetes appear to be at elevated risk of atherothrombotic events. Objectives  The purpose of this study was to determine the effect of antiplatelet therapy with ticagrelor on recurrent ischemic events in patients with diabetes and prior myocardial infarction (MI). Methods  We examined the subgroups of patients with diabetes (n = 6,806) and without

- 06/2016

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation

giugno 2016|News, Update cardiologico|0 Comments

Direct oral anticoagulants (DOACs) have been used in clinical practice in the United States for the last 4 to 6 years. Although DOACs may be an attractive alternative to warfarin in many patients, long-term outcomes of use of these medications are unknown. We performed a propensity-matched analysis to report patient important outcomes of death, stroke/transient ischemic

- 05/2016

Presentazione del progetto FACT sulla Fibrillazione atriale

maggio 2016|News, Update cardiologico|0 Comments

  Cari soci Ance ho il piacere e l’onore , come anticipato alla riunione dei nostri quadri tenutasi il 22/23 aprile , di comunicarvi l’avvio di un importante studio, in cooperazione con l’AIAC, sulla fibrillazione atriale: lo studio FACT . A fine maggio partiranno in quattro regioni ( Sardegna ,Triveneto, Sicilia e Campania ) le

- 04/2016

A New Electrocardiographic Marker of Sudden Death in Brugada SyndromeThe S-Wave in Lead I

aprile 2016|News, Update cardiologico|0 Comments

Abstract Background  Risk stratification in asymptomatic patients remains by far the most important yet unresolved clinical problem in the Brugada syndrome (BrS). Objectives  This study sought to analyze the usefulness of electrocardiographic parameters as markers of sudden cardiac death (SCD) in BrS. Methods  This study analyzed data from 347 consecutive patients (78.4% male; mean age